What's Happening?
Vivian Ott, a scientist at the ZHAW Zurich University of Applied Sciences, is advancing the field of biopharmaceutical production through the development and scale-up of CHO cell-based fed-batch and perfusion processes. Her work, which spans from milliliter to 200-liter scales, focuses on process intensification strategies for antibody manufacturing. Ott's research is pivotal in supporting development and technology transfer activities, contributing to the efficient production of monoclonal antibodies using perfusion culture and Repligen's XCell ATF technology.
AD
Why It's Important?
The advancements in perfusion-based monoclonal antibody production are crucial for the biopharmaceutical industry, as they offer potential improvements in efficiency and scalability. This technology can lead to more cost-effective and rapid production of therapeutic antibodies, which are essential in treating various diseases, including cancer and autoimmune disorders. The ability to scale up production processes effectively can enhance the availability of these critical treatments, benefiting healthcare providers and patients alike.
